Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 11/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71331 | 0.82 | PDE4D (0.65) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL7336558 | 0.81 | PDE4D (0.64) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL1457706 | 0.80 | KMT2A (0.73) | KMT2APDE4BPDE4DMAPK14PDE4A | |
| SCHEMBL28275397 | 0.77 | TUBB4A (0.55) | KMT2A | |
| SCHEMBL219096 | 0.77 | TUBB4A (0.55) | KMT2A | |
| SCHEMBL7356246 | 0.76 | PDE4D (0.46) | KMT2APDE4BPDE4DMAPK14PDE4A | |
| SCHEMBL14218378 | 0.75 | TPMT (0.47) | KMT2APOLB | |
| SCHEMBL7462332 | 0.74 | KMT2A (0.51) | KMT2APDE4BPDE4DPDE4APDE4C | |
| SCHEMBL7418490 | 0.74 | PDE4B (0.49) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| Tetrahydrofuran SCHEMBL28731511 | 0.73 | MAPT (0.53) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419138-B1 | N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL BENZAMIDE DERIVATIVES | ORGANON NV (NL) | 2008-10-29 | — | — | EP | disclosed |
| US-7126027-B2 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | AKZO NOBEL N.V. (NL) | 2006-10-24 | — | — | US | disclosed |
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | N.V. ORGANON (NL) | 2004-12-02 | — | — | US | disclosed |
| EP-1419138-A1 | N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | Akzo Nobel (NL) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003010132-A1 | N-[(1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | SLC1A2, SLC6A1, KCNT2 | KMT2A 288/4885PDE4B 3176/4885PDE4D 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.